Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 202 participants in total, spread across five different treatment groups. The groups varied in whether participants received the study drug relamorelin, a placebo (an inactive substance), or a combination of both across different stages of the trial. The trial was primarily measuring how many participants experienced notable medical events, unusual laboratory test results, changes in vital signs (such as blood pressure and heart rate), or unusual heart-tracing (ECG) results while on the study drug. The reported data shows that when it came to unwanted medical events that appeared or worsened during treatment — known as "treatment-emergent adverse events" — the numbers ranged across the five groups: 16, 11, 27, 27, and 16 participants respectively reported at least one such event. For laboratory test results that were flagged as potentially clinically significant (meaning they stood out enough for the investigator to take note), the reported data shows very small numbers — mostly zero participants per group, with a handful of isolated individual results noted in certain groups. For vital signs, the reported data shows that no participants in any group were recorded as having clinically meaningful trends. Similarly, for heart-tracing (ECG) results, no participants in any group were recorded as having clinically meaningful trends. It is worth noting that the data shows zero participants recorded as having "completed" the trial in the conventional sense, which may reflect how the study's completion was defined and recorded rather than participants dropping out. These summary numbers are what was submitted to the registry and do not include further context about the nature of individual events. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Gastroparesis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have already successfully completed one of two specific earlier related studies (called RLM-MD-03 or RLM-MD-04)
- You must be able to read and sign a consent form agreeing to take part before any study activities begin, and be willing and able to follow the study's requirements
- You must have followed the rules and procedures of the earlier study well enough, as judged by the study doctor
Who may not be able to join:
- You are planning to take part in another study involving an experimental drug or medical device at any point during this trial
- You have an ongoing health concern or abnormal test result (such as a physical exam finding, blood test, or heart tracing) left over from the earlier study that the study doctor feels could affect your ability to take part safely
- You have any other condition or situation that the study doctor believes could affect the study results or put you at risk, including serious kidney, liver, or heart and lung problems
- You are currently pregnant, breastfeeding, or planning to become pregnant during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Harvy Schneier, Allergan
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs); Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results; Number of Participants With Clinically Meaningful Trends for Vital Signs; Number of Participants With Clinically Meaningful Trends in Electrocardiogram (ECG) Results
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.